NCT01802918View on ClinicalTrials.gov

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 18, 2013

Primary Completion Date

November 21, 2013

Study Completion Date

November 21, 2013

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

GSK2838232

Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily

DRUG

Placebo

Visually matching GSK2838232

DRUG

Ritonavir

100mg tablets once daily for 12 days

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01802918 - Single Dose Escalation Study of GSK2838232 in Healthy Subjects | Biotech Hunter | Biotech Hunter